Korean J Crit Care Med.  2015 Nov;30(4):323-328. 10.4266/kjccm.2015.30.4.323.

Disseminated Gastrointestinal Mucormycosis in Immunocompromised Disease

• Ha TS
• Park CM
• Yang JH
• Cho YH
• Chung CR
• Jeon K
• Suh GY

• KMID: 2156189
• DOI: http://doi.org/10.4266/kjccm.2015.30.4.323

Abstract

Mucormycosis is an uncommon opportunistic fungal infection mostly affecting immunocompromised patients and gastrointestinal mucormycosis is a rare and life-threatening. We describe a 31-year-old man with a history of idiopathic cyclic neutropenia who developed perforations of the stomach and intestine and intra-abdominal bleeding due to disseminated gastrointestinal mucormycosis after the initial operation.

Keyword

gastrointestinal tract; immunocompromised host; mucormycosis

MeSH Terms

Adult
Gastrointestinal Tract
Hemorrhage
Humans
Immunocompromised Host
Intestines
Mucormycosis*
Neutropenia
Stomach

Figure

• 

  Fig. 1. Black ulcer with full bowel infarction of the small intestine (arrow) on the exposed specimen taken during the second operation.

• 

  Fig. 2. Microscopic findings of the resected small bowel. (A) Microscopic findings of the small bowel showed vasculitis and transmural infarction (staining, H&E; magnification, x40), (B) GMS staining revealed broad, irregular and non-septate fungal hyphae (staining, GMS; magnification. x200). H&E: Hematoxylin and eosin; GMS: Gomori’s methenamine-silver stain.

• 

  Fig. 3. Necrosis of the omentum and perforation of the transverse colon.

• 

  Fig. 4. Multiple perforations of the small bowel discovered during the sixth operation.

Reference

References

1. Petrikkos G, Skiada A, Lortholary O, Roilides E, Walsh TJ, Kontoyiannis DP. Epidemiology and clinical manifestations of mucormycosis. Clin Infect Dis. 2012; 54 Suppl 1:S23–34.

2. Gonzalez CE, Rinaldi MG, Sugar AM. Zygomycosis. Infect Dis Clin North Am. 2002; 16:895–914. vi.

3. Petrikkos G, Drogari-Apiranthitou M. Zygomycosis in Immunocompromised non-Haematological Patients. Mediterr J Hematol Infect Dis. 2011; 3:e2011012.

4. Prabhu RM, Patel R. Mucormycosis and entomophthoramycosis: a review of the clinical manifestations, diagnosis and treatment. Clin Microbiol Infect. 2004; 10 Suppl 1:31–47.

5. Ribes JA, Vanover-Sams CL, Baker DJ. Zygomycetes in human disease. Clin Microbiol Rev. 2000; 13:236–301.

6. Roden MM, Zaoutis TE, Buchanan WL, Knudsen TA, Sarkisova TA, Schaufele RL, et al. Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clin Infect Dis. 2005; 41:634–53.

7. Agha FP, Lee HH, Boland CR, Bradley SF. Mucormycoma of the colon: early diagnosis and successful management. AJR Am J Roentgenol. 1985; 145:739–41.

8. Lo OS, Law WL. Ileocolonic mucormycosis in adult immunocompromised patients: a surgeon’s perspective. World J Gastroenterol. 2010; 16:1165–70.

9. Lee SH, Son YG, Sohn SS, Ryu SW. Successful treatment of invasive gastric mucormycosis in a patient with alcoholic liver cirrhosis: a case report. Exp Ther Med. 2014; 8:401–4.

10. Yang YC, Park CK, Kim JS, Park NH, Lee SH, Kim SR, et al. A case of mucormycosis colonization associated with giant gastric ulcer. Korean J Gastrointest Endosc. 2000; 20:49–52.

11. Han JY, Cheon JH, Kim DH, Chon HJ, Kim SK, Kim TI, et al. Ileal mucormycosis diagnosed by colonoscopy in a patient with acute myeloid leukemia. Korean J Gastroenterol. 2008; 52:179–82.

12. Suh IW, Park CS, Lee MS, Lee JH, Chang MS, Woo JH, et al. Hepatic and small bowel mucormycosis after chemotherapy in a patient with acute lymphocytic leukemia. J Korean Med Sci. 2000; 15:351–4.

13. Kontoyiannis DP, Wessel VC, Bodey GP, Rolston KV. Zygomycosis in the 1990s in a tertiary-care cancer center. Clin Infect Dis. 2000; 30:851–6.

14. Kontoyiannis DP, Lewis RE. Invasive zygomycosis: update on pathogenesis, clinical manifestations, and management. Infect Dis Clin North Am. 2006; 20:581–607. vi.

15. Spellberg B, Walsh TJ, Kontoyiannis DP, Edwards J Jr, Ibrahim AS. Recent advances in the management of mucormycosis: from bench to bedside. Clin Infect Dis. 2009; 48:1743–51.

16. Gómez-López A, Cuenca-Estrella M, Monzón A, Rodriguez-Tudela JL. In vitro susceptibility of clinical isolates of Zygomycota to amphotericin B, flucytosine, itraconazole and voriconazole. J Antimicrob Chemother. 2001; 48:919–21.

17. van Burik JA, Hare RS, Solomon HF, Corrado ML, Kontoyiannis DP. Posaconazole is effective as salvage therapy in zygomycosis: a retrospective summary of 91 cases. Clin Infect Dis. 2006; 42:e61–5.

18. Liles WC, Huang JE, van Burik JA, Bowden RA, Dale DC. Granulocyte colony-stimulating factor administered in vivo augments neutrophil-mediated activity against opportunistic fungal pathogens. J Infect Dis. 1997; 175:1012–5.

19. Garcia-Diaz JB, Palau L, Pankey GA. Resolution of rhinocerebral zygomycosis associated with adjuvant administration of granulocyte-macrophage colony-stimulating factor. Clin Infect Dis. 2001; 32:e145–50.

20. Vaes M, Hites M, Cotton F, Bourguignon AM, Csergö M, Rasson C, et al. Therapeutic drug monitoring of posaconazole in patients with acute myeloid leukemia or myelodysplastic syndrome. Antimicrob Agents Chemother. 2012; 56:6298–303.